Wonderful to see the FDA, TGA and Canadian regulatory authorities working together to approve a new treatment for refractory/ relapsed Chronic Lymphocytic Leukaemia (CLL). Acalabrutinib is a second-generation BTK (Bruton’s tyrosine kinase or tyrosine-protein kinase) and was shown to be more effective and more tolerable than usual treatments. We look forward to seeing this treatment made available in Australia.
https://www.tga.gov.au/media-release/acalabrutinib-receives-tga-approval-cll-and-sll-cancers